Privacy Policy

Effective Date: 12/9/2019

 

Agile Therapeutics (“Agile”) is committed to maintaining the privacy and security of your personal information, and we appreciate that medical information is particularly sensitive. This Privacy Policy applies to the Agile website at www.agiletherapeutics.com (the “Website”). Agile respects the privacy of its Website visitors (“Visitors”). This Privacy Policy discloses Agile’s information collection and dissemination practices in connection with the Website and applies solely to the information that we collect through the Website. This Privacy Policy does not address personal information that you provide to us in other contexts (e.g., through a business relationship not handled through the Website).

Acceptance of Privacy Policy

By using this Website, you signify your acceptance of this Privacy Policy. If you do not agree to the terms of this Privacy Policy, please do not use the Website. Your continued use of the Website following the posting of changes to these terms will mean that you accept those changes.

Personal Information Provided by You

Agile collects your personally identifiable information (“PII”) through the Website when you choose to provide such information and as described below in this Privacy Policy. We may collect PII from you when you register on the Website, place an order for products or services if and when they become available, respond to communications such as e-mail, sign up to join consumer research or other panels, or participate in another site feature.

Use and Disclosure of Personal Information

Agile will not sell, rent, license, or trade your PII with third parties for their own direct marketing use unless we receive your express consent to do so. Unless you give us permission to do so, Agile will not share your PII other than as specified in this Privacy Policy.

We may use the information we collect from you when you sign up, register, purchase products or services, respond to a survey or marketing communication, surf the Website, or use certain other Website features in the following ways:

To personalize your Website experience and to allow us to deliver the type of content and product offerings in which you are most interested.

To allow us to better service you in responding to your customer service requests.

To enroll you in a consumer research or other panel.

To administer a promotion, survey or other Website feature.

Disclosures to Third Parties Assisting In Our Operations. Agile may share your PII under confidentiality agreements with other companies that work with, or on behalf of, Agile to provide products and services, such as a cloud hosting service or a document storage company. These companies may use your PII to assist Agile in its operations. However, these companies do not have any independent right to share this information.

Disclosures Under Special Circumstances. We may provide information about you to respond to subpoenas, court orders, legal process or governmental regulations, or to establish or exercise our legal rights or defend against legal claims. We believe it is necessary to share information in order to investigate, prevent or take action regarding illegal activities, suspected fraud, situations involving potential threats to the physical safety of any person, or as otherwise required by law.

Business Transfers. We may share your PII with other business entities in connection with the sale, assignment, merger or other transfer of all or a portion of Agile’s business to such business entity. We will require any such successor business entity to honor the terms of this Privacy Policy.

Automatically Collected Information and Anonymous Information

Each time a visitor comes to a Website, Agile collects some information to improve the overall quality of the visitor’s online experience.

Aggregated Data. Agile collects aggregate queries for internal reporting and also counts, tracks, and aggregates the visitor’s activity into Agile’s analysis of general traffic flow at the Website. To these ends, Agile may merge information about you into aggregated group data. In some cases, Agile may remove personal identifiers from PII and maintain it in aggregate form that may later be combined with other information to generate anonymous, aggregated statistical information. Such anonymous group data may be shared on an aggregated basis with Agile’s affiliates, business partners, service providers and/or vendors; if it does so, Agile will not disclose your individual identity.

Web Server Logs and IP Addresses. An Internet Protocol (“IP”) address is a number that automatically identifies the computer/machine you have used to access the Internet. The IP address enables our server to send you the web pages that you want to visit, and it may disclose the server owned by your Internet Service Provider. Agile may use IP addresses to conduct Website analyses and performance reviews and to administer the Website.

Cookies and Web Beacons. Cookies are pieces of information that a website transfers to a user’s computer for purposes of storing information about a user’s preferences. Cookies in and of themselves do not personally identify users, although they do identify a user’s computer. Many websites use cookies as a standard practice to provide useful features when a user visits the website and most web browsers are set up to accept cookies. Agile uses cookies to improve your online experience when visiting the Website. You can set your browser to refuse cookies, but some portions of a Website may not work properly if you refuse cookies. Some of the Website’s web pages may use web beacons in conjunction with cookies to compile aggregate statistics about Website usage. A web beacon is an electronic image (also referred to as an “action tag,” “single-pixel,” or “clear GIF”) that is commonly used to track the traffic patterns of users from one web page to another in order to maximize web traffic flow and to otherwise analyze the effectiveness of website. Some web beacons may be unusable if you elect to reject their associated cookies.

Retention Period

Agile will retain the information it collects as long as necessary to fulfill its legitimate business purposes, unless longer retention is required or allowed to fulfill legal obligations.

Referrals/Links

The Website may contain links to third-party websites that may offer information of interest. This Privacy Policy does not apply to those websites, and Agile recommends reviewing those websites’ privacy policies individually.

Security

Agile understands that storing our data in a secure manner is essential. Agile stores PII and other data using industry standard physical, technical and administrative safeguards to secure data against foreseeable risks, such as unauthorized use, access, disclosure, destruction or modification. Please note, however, that while Agile has endeavored to create a secure and reliable website for users, the confidentiality of any communication or material transmitted to/from the Website or via e-mail cannot be guaranteed.

Response to “Do Not Track” Signals

Some Internet browsers include the ability to transmit “Do Not Track” signals.  Since uniform standards for “Do Not Track” signals have not yet been adopted, Agile does not process or respond to “Do Not Track” signals.

Children’s Privacy Protection

Under Age 13

Agile understands the importance of protecting children’s privacy in the interactive online world. This Website is not designed for, or intentionally targeted at, children under 13 years of age. It is not our policy to intentionally collect or maintain information about anyone under the age of 13. No one under the age of 13 should submit any PII to Agile or this Website.

Under Age 18

Minors under 18 years of age or their parent or guardian may have the PII that they have provided to Agile through the Website deleted by sending an email to info@agiletherapeutics.com requesting deletion. Please note that, while we make reasonable efforts to comply with such requests, deletion of your personal information does not ensure complete and comprehensive removal of that data from all systems.

Important Notices to Non-United States Residents

It is important to note that the Website is operated in the United States. If you are located outside of the United States, please be aware that any PII you provide to us will be transferred to the United States. By using the Website and/or providing us with your PII, you consent to this transfer.

Changes

You may review and request changes to your PII that Agile has collected, including the removal of your PII from Agile’s databases in order to prevent receipt of future communications using any of the following option:

You can send your request via e-mail to info@agiletherapeutics.com.

Policy Updates

This Privacy Policy may be revised from time to time as we add new features and services, as laws change, and as industry privacy and security best practices evolve. We display an effective date on the policy in the upper right corner of this Privacy Policy so that it will be easier for you to know when there has been a change. If we make any change to this Privacy Policy regarding use or disclosure of PII, we will provide advance notice on this Website. Small changes or changes that do not significantly affect individual privacy interests may be made at any time and without prior notice.

Questions?

If you have any questions about this Privacy Policy or about Agile’s handling of your information, please contact info@agiletherapeutics.com or (609) 683-1880.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

  • Do not use TWIRLA if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects from combination hormonal contraceptives (CHCs), including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.
  • Do not use TWIRLA if your body mass index (BMI) is 30 kg/m2 or more. If you do not know what your BMI is, please talk to your healthcare provider. Women with a BMI of 30 kg/m2 or more who use CHCs may have a higher risk for developing side effects like blood clots compared to women with a BMI lower than 30 kg/m2.

Who should not use TWIRLA?

Do not use TWIRLA if you have or have had blood clots; history of heart attack or stroke, high blood pressure that medicine cannot control, any condition that makes your blood clot more than normal, or certain heart valve problems; smoke and are over 35 years old; BMI ≥ 30 kg/m2.

TWIRLA is also not for women who have diabetes and are over 35 years old, diabetes with high blood pressure or kidney, eye, nerve, or blood vessel damage, diabetes for longer than 20 years; have had breast cancer or any cancer that is sensitive to female hormones; certain kinds of severe migraine headaches; have liver problems or liver tumors; unexplained bleeding from the vagina; who are or may be pregnant; or who take hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, as this may increase levels of liver enzymes in the blood.

TWIRLA may not be a good choice for you if you have ever had depression; jaundice (yellowing of the skin or eyes) caused by pregnancy (also called cholestasis of pregnancy) or related to previous use of hormonal birth control.

What are the most serious side effects of TWIRLA?

TWIRLA increases the risks of serious side effects, including blood clots, stroke, or heart attack especially in women who have other risk factors. These can be life-threatening or lead to permanent disability. This increased risk is highest when you first start using hormonal birth control and when you restart the same or different hormonal birth control after not using it for a month or more. Treatment with TWIRLA should be stopped at least 4 weeks before and through 2 weeks after major surgery.

What are the most common side effects of TWIRLA?

The most common side effects reported by women using TWIRLA in a study were skin reactions at the patch site, nausea, headache, menstrual cramps, and weight gain.

These are not all the possible side effects of TWIRLA. Call your healthcare provider for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

What else should I know about TWIRLA?

TWIRLA is a birth control patch for women with a BMI less than 30 kg/m2 who can become pregnant. It contains two female hormones, a progestin called levonorgestrel, and an estrogen called ethinyl estradiol. TWIRLA may not be as effective in women with a BMI of 25 kg/m2 or more. If you have a BMI of 30 kg/m2 or more, please talk with your health care provider about which method of birth control is right for you.

You should not use TWIRLA any earlier than 4 weeks after having a baby or if you are breastfeeding.

Hormonal birth control methods help to lower the chances of becoming pregnant when taken as directed. They do not protect against HIV infection (AIDS) and other sexually transmitted infections (STIs).

The risk information provided here is not complete. To learn more, review the TWIRLA Patient Information and talk with your healthcare provider or pharmacist.